海外の治験の状況「前立腺癌」での検索結果
242件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- The use of Peroxisome Proliferator Activator Receptor Agonists in the management of Androgen Independent Prostate Cancer - PPAR
- The use of Peroxisome Proliferator Activator Receptor Agonists in the management of Androgen Independent Prostate Cancer. Open-labeled, non-randomised clinical trial in patients with androgen independent prostate cancer
- United Kingdom
- 2006-03-31
Authorised
- Diagnostic imaging in prostate cancer (as in tumours with accelerated menbrane turn-over)by F-18 Fluoro-metil-choline PET/CT
- patients with prostate cancer istologically proven MedDRA version: 14.1 Level: SOC Classification code 10038359 Term: Renal and urinary disorders System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 14.1 Level: SOC Classification code 10022891 Term: Investigations System Organ Class: 10022891 - Investigations ;Therapeutic area: Diseases [C] - Cancer [C04]
- Italy
- 2012-10-25
Authorised
- [11C]-choline PET/CT imaging in prostate cancer patients
- Prostate adenocarcinoma accounts for 11% of all malignancies, with a total 2.6 million new cases / year estimated in Europe. Mortality rate is 30.6 / 100,000 persons/year. Prostate cancer generally evolves relatively slow and as a result of local growth, the tumor may infiltrate the closest pelvic structures ; besides the frequent metastatic involvement of pelvic lymph nodes, this cancer can metastasize through the bloodstream, with a marked preference for the skeleton. MedDRA version: 14.1 Level: LLT Classification code 10066489 Term: Progression of prostate cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Italy
- 2013-05-02
Authorised
- Pharmacogenetic study in castration-resistant prostate cancer patients treated with abiraterone acetate
- Prostate cancer metastatic MedDRA version: 14.1 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- France
- 2013-04-19
Authorised
- Optimal patients with Metastasized Hormone Resistant Prostate Cancer Previously Treated with Docetaxel
- Metastasized Castration Resistant Prostate Cancer br>MedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: PT Classification code 10036911 Term: Prostate cancer recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: LLT Classification code 10066489 Term: Progression of prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: LLT Classification code 10076506 Term: Castration-resistant prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: PT Classification code 10062904 Term: Hormone-refractory prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Netherlands
- 2017-01-09
Authorised
- An Investigational Immunotherapy Study to Determine Which Combination of Nivolumab plus Several Other Drugs, is the Most Effective in Treating Castration-resistant Prostate Cancer That Has Spread
- Castration-resistant Metastatic Prostate Cancer br>MedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: LLT Classification code 10076506 Term: Castration-resistant prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Brazil, Canada, Chile, Colombia, France, Germany, Mexico, Spain
- 2017-12-01
Authorised
- Prostate cancer with OligometaSTatic relapse: Combining stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736), a randomized phase II trial
- oligometastatic hormone sensitive prostate cancer br>MedDRA version: 20.0 Level: LLT Classification code 10007463 Term: Carcinoma prostatic System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12]
- France
- 2018-01-19
Authorised
- Intra-individual dose escalation of abiraterone acetate according to its concentration in blood in patients with progressive castration-resistant metastatic prostate cancer
- Metastatic castration-resistant prostate carcinoma men, aged >/= 18 years MedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- France
- 2018-01-12
Authorised
- A study to provide access to continued treatment for subjects with prostate cancer who are currently participating in an enzalutamide clinical study
- metastatic castration-resistant prostate cancer br>MedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Belgium, Canada, Chile, Czech Republic, Denmark, Finland, France, Georgia, Germany, Israel, Italy, Japan, Korea, Republic of, Lithuania, Moldova, Republic of, Netherlands, New Zealand, Russian Federation, Slovakia, South Africa, Spain, Sweden, Taiwan, United Kingdom, United States
- 2016-09-30
Authorised
- Study of the analgesic efficacy of the association zoledronic acid and 153Sm-lexidronam in patients with skeletal metastases from prostatic cancer
- Population enrolled in the study is represented by patients bearing advanced prostatic cancer with skeletal metastases and bone pain cancer-associated and treated with analgesic drugs MedDRA version: 14.1 Level: LLT Classification code 10005993 Term: Bone metastases System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Italy
- 2012-03-07
